Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.

Metabolic and alcohol-related liver disease (MetALD) is a newly defined entity within the spectrum of steatotic liver disease, characterized by the interplay of cardiometabolic risk factors and alcohol consumption. The evolving epidemiology and complex pathophysiology of MetALD present unique challe...

Descripción completa

Detalles Bibliográficos

Publicado en:	Nature Reviews Gastroenterology & Hepatology Vol. 22; no. 12; pp. 866 - 885
Autores principales:	Diaz, Luis Antonio, Thiele, Maja, Louvet, Alexandre, Lee, Brian P., Ajmera, Veeral, Tavaglione, Federica, Hsu, Cynthia L., Huang, Daniel Q., Pose, Elisa, Bataller, Ramon, McClain, Craig, Mellinger, Jessica, Tincopa, Monica, Mitchell, Mack C., Ratziu, Vlad, Rinella, Mary E., Sarin, Shiv K., Shah, Vijay H., Szabo, Gyongyi, Wong, Vincent Wai-Sun
Formato:	Journal Article
Publicado:	Springer Nature Dec2025
Acceso en línea:	Ver este registro en EBSCOhost